First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 6, Issue SUPPL. 2, 2007, Pages

  Lee, James J ^a   Chu, Edward ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Bevacizumab; Cetuximab; FOLFIRI; FOLFOX; Immunoglobulin; Panitumumab

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB;

ABDOMINAL PAIN; ACNE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURGERY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INFUSION; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; INFECTION; LUNG EMBOLISM; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; SKIN TOXICITY; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 37049032136     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2007.s.001     Document Type: Article

References (22)

1. Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft: model. Clin Cancer Res 1995; 1:1311-8.
2. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001; 13:506-13.
3. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59:1935-40.
4. Wu X, Fan Z, Masui H, et al. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 1995; 95:1897-905.
5. Wu X, Rubin M, Fan Z, et al. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 1996; 12:1397-403.
6. Liu B, Fang M, Schmidt M, et al. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br J Cancer 2000; 82:1991-9.
7. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000; 6:2166-74.
8. Naramura M, Gillies SD, Mendelsohn J, et al. Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother 1993; 37:343-9.
9. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
10. Díaz Rubio E, Tabernero J, van Cutsem E, et al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international phase II study. J Clin Oncol 2005; 24(18 suppl):254s (Abstract 3535).
11. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer: a North American Intergroup trial. J Clin Oncol 2004; 22:23-30.
12. Rosenberg AH, Loehrer PJ, Needle M, et al. Erbitux (IMC-225) plus weekly irinotecan (CPT-11), fluorouracil (5-FU), and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol 2002; 21:135a (Abstract 536).
13. Folprecht G, Lutz MP, Schoffski P, et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17:450-6.
14. Rougier P, Raoul JL, Van Laethem JL, et al. Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. Proc Am Soc Clin Oncol 2004; 23:248 (Abstract 3513).
15. Saltz LB, Lenz H, Hochster H, et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. J Clin Oncol 2005; 23(16 suppl):248s (Abstract 3508).
16. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J Clin Oncol 2007; 25(18 suppl):164s (Abstract 4000).
17. Venook A, Niedzwiecki D, Hollis D, et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. J Clin Oncol 2006; 25(18 suppl):148s (Abstract 3509).
18. Berlin J, Malik I, Picus J, et al. Panitumumab therapy with irinotecan, 5-fluorouracil, and leucovorin (IFL) in patients (pts) with metastatic colorectal cancer (mCRC). Ann Oncol 2004; 15(suppl 3):iii70 (Abstract 265).
19. Berlin J, Posey J, Tchekmedyian S, et al. First line therapy of panitumumab, a fully human antibody, in combination with FOLFIRI for the treatment of metastatic colorectal cancer (mCRC). Eur J Cancer Supplements 2005; 3:185 (Abstract 653).
20. Amgen discontinues Vectibix™ treatment in PACCE trial evaluating Vectibix™ as part of triple combination regimen. Preliminary pre-planned interim analysis shows negative effect on progression-free survival [press release]. Amgen; March 22, 2007. Available at: http://www.amgen.com/media/ media_pr_detail.jsp?releaseID=977186.
21. Hecht R, Chidiac T, Mitchell E, et al. An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (bev) for metastatic colorectal cancer (mCRC). Presented at: the 9th World Congress on Gastrointestinal Cancer; June 27-30, 2007; Barcelona, Spain.
22. Schrag D. The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med 351:317-9.